Brise Pharmaceuticals 与 AbbVie 推进下一代偏头痛疗法全球许可协议
Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
Brise Pharmaceuticals 就其与 AbbVie 于2024年签订的独家许可协议作出更新，Brise 负责两项临床前偏头痛项目的发现工作，AbbVie 主导全球开发与商业化。协议包含开发、商业、监管及销售里程碑，合计潜在交易价值最高可达 7.57 亿美元，另加未来销售分成。Brise 已有多个近期里程碑达成，其口服小分子 BR005 正在成人急性偏头痛关键临床试验中。
, /PRNewswire/ -- Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration agreement, Brise is responsible for discovery efforts and AbbVie will lead global development and commercialization activities for two of Brise's preclinical migraine programs.
"This collaboration represents an important validation of our research platform in migraine and advances our mission to deliver potentially transformative medicines to patients," said Guochun Li, Chief Executive Officer of Brise Pharmaceuticals. "By partnering with a global leader like AbbVie, we can maximize the value of our discovery engine while continuing to invest in the next wave of innovative therapies."
Under the terms of this agreement, the aggregated potential transaction value, including development, commercial, regulatory and sales milestones, could reach up to US $757 million plus royalties on future sales. As of the date of this announcement, Brise has already achieved several near-term milestones.
About Brise Pharmaceuticals
Founded in June 2021 in Shanghai, China, Brise Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering multi-modality therapeutics to transform the treatment landscape for debilitating pain conditions. The company's mission is to develop innovative and highly differentiated treatments, with the aim to systematically improve pain management and quality of life for patients living with migraine, nociceptive, neuropathic, and nociplastic pain.
Utilizing its research and discovery engine, Brise integrates small molecules and targeted antibodies therapeutics to modulate complex pain pathways at the molecular level. The company's pipeline currently features BR005, a novel China-originated, oral small-molecule, which is currently in pivotal clinical trials for acute treatment of migraine in adults, as well as a diverse portfolio of next-generation innovative therapeutic candidates advancing toward IND.
Learn more about the company's therapeutic pipelines at https://www.brisepharma.com/.
SOURCE Brise Pharmaceuticals Co., Ltd.
来源：PR Newswire Health · prnewswire.com